Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)

Sutro Biopharma has reported Cash from Financing Activities for 9 years, with the latest figure at -$64000.0 in Q4 2025.

• Quarterly Cash from Financing Activities fell 166.67% year-over-year to -$64000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44000.0 (down 99.95% YoY) and the FY2025 annual result came in at $44000.0, down 99.95% from the prior year.
• Cash from Financing Activities retreated to -$64000.0 in Q4 2025 per STRO's latest filing, from $102000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $137.7 million in Q2 2023 and troughed at -$5.7 million in Q3 2023.
• A 5-year average of $14.2 million and a median of $633000.0 in 2021 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 14164.1% in 2022, then tumbled 166.67% in 2025.
• Over 5 years, Cash from Financing Activities stood at $506000.0 in 2021, then jumped by 2315.22% to $12.2 million in 2022, then slumped by 125.57% to -$3.1 million in 2023, then soared by 99.23% to -$24000.0 in 2024, then plunged by 166.67% to -$64000.0 in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$64000.0, $102000.0, and -$60000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.